Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Inotuzumab ozogamicin, sold under the brand name Besponsa, is an antibody-drug conjugate medication used to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). It is administered by intravenous infusion.
Read the full article on WikipediaAcute lymphoblastic leukaemia Clinical criteria: Treatment Phase: Consolidation treatment Patient must have previously received PBS-subsidised induction treatment with this drug for this condition, AND Patient must have achieved a complete remission; OR Patient must have achieved a complete remission with partial haematological recovery, AND The treatment must not be more than 5 treatment cycles under this restriction in a lifetime, AND Patient must not receive PBS-subsidised treatment with this drug if progressive disease develops while on this drug. This drug is not PBS-subsidised if it is administered to an in-patient in a public hospital setting. The treatment must not exceed 0.5mg per m2 for all doses within a treatment cycle Treatment with this drug for this condition must not exceed 6 treatment cycles in a lifetime.
“12.3 days”
Working under the parallel aged-care framework? Aged-care equivalent →